Theriva Biologics
Rockville, Maryland, United States · Biopharma, Biotechnology, Health Care
Theriva Biologics, Inc. was formerly known as Synthetic Biologics, Inc. Theriva™ is a clinical-stage immuno-oncology company developing oncolytic viruses intended to overcome the protective barrier surrounding solid tumors and selectively kill tumor cells. Our developmental therapies stem from the laboratory of Dr. Ramon Alemany, recognized world-wide as a key opinion leader in adenovirus technolo
Key facts
- Headquarters
- Rockville, Maryland, United States
- Employees
- 22
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (TOVX)
- Website
- therivabio.com
- Company page
Recent activity at Theriva Biologics
- : SEC 8-K (1.01): On October 30, 2026, Theriva Biologics, Inc. entered into a Material Definitive Agreement with Biossil Labs Inc. for the sale of assets related to the oral β-lactamase product candidate SYN-004 and the carbapenemase product candidate SYN-006. The closing of the transaction was simultaneous with the signing of the agreement, which involved an upfront payment of $350,000 from Biossil. Additionally, the agreement includes potential regulatory milestone payments up to $3 million and sales milestones totaling up to $88 million, along with running royalties on worldwide net sales of the products derived from the purchased assets. This strategic agreement allows Biossil to exploit the intellectual property rights and related assets while Theriva retains certain liabilities not assumed by Biossil.
- : SEC 8-K (8.01): On August 6, 2026, Theriva Biologics, Inc. announced the dosing of the first patient in the VIRAGE2 clinical trial, which is a small proof-of-concept study evaluating more frequent dosing of VCN-01 (zabilugene almadenorepvec) in metastatic pancreatic ductal adenocarcinoma (PDAC) patients receiving standard of care chemotherapy with gemcitabine/nab-paclitaxel. The trial aims to complete enrollment in H2 2026, with initial safety and pharmacodynamic data expected by Q3 2027. The findings from this trial, inspired by previous observations in the VIRAGE Phase 2b trial, could impact VCN-01's dosing strategy in future pivotal trials. This progress reflects the regulatory acknowledgment from both EMA and FDA regarding potential clinical benefits of the drug.
- : SEC 8-K (5.02): On August 3, 2026, Theriva Biologics, Inc. held its 2026 Annual Meeting of Stockholders where an amendment (Amendment No. 4) to the 2020 Stock Incentive Plan was approved. This amendment increased the number of shares authorized for grant from 4,500,000 to 6,500,000 shares of common stock. Additionally, four directors were elected to serve until the next annual meeting. The event is significant as it reflects the company's commitment to incentivizing its management team and aligning their interests with shareholders.
- : SEC 8-K (8.01): On July 7, 2026, Theriva Biologics, Inc. announced via press release that the AEMPS has authorized the initiation of the VIRAGE2 clinical trial. This trial will assess a new dosing schedule of zabilugene almadenorepvec (VCN-01) in combination with gemcitabine/nab-paclitaxel for patients with newly-diagnosed metastatic pancreatic cancer. It builds on promising outcomes from a previous trial, VIRAGE Phase 2b, which demonstrated improved survival rates when VCN-01 was administered twice compared to standard chemotherapy alone. The VIRAGE2 trial aims to evaluate the possibility of administering at least three doses of VCN-01 spaced two months apart, potentially paving the way for a future Phase 3 clinical trial. The event date of July 7, 2026 places this filing within the required timeframe.
- : SEC 8-K (7.01): On July 7, 2026, Theriva Biologics, Inc. announced via a press release that it received authorization from the Spanish Agency of Medicines and Medical Devices (AEMPS) to initiate the VIRAGE2 clinical trial. This trial will evaluate zabilugene almadenorepvec (VCN-01) in combination with gemcitabine/nab-paclitaxel in patients with newly-diagnosed metastatic pancreatic cancer. The VIRAGE2 trial follows the results of the prior VIRAGE Phase 2b clinical trial involving 112 patients. The strategic implication of this authorization is significant as it positions Theriva to advance its treatment protocol for an aggressive cancer type, potentially bolstering its clinical portfolio and investor confidence.
- : SEC 8-K (8.01): On June 11, 2026, Theriva Biologics, Inc. announced the clinical and translational results from the VCN-01 Phase 1 clinical trial in HNSCC via a press release. The trial involved 20 adult patients with refractory or metastatic HNSCC, with notable findings indicating median progression-free survival ranging from 1.6 to 3.7 months across different trial arms, and median overall survival from 10.3 to 17.3 months. The study highlighted significant biological activity of VCN-01, evidenced by marked increases in the enzyme PH20 and viral genome levels in the patients' blood, as well as changes in immune cell markers correlating with improved patient outcomes. These results imply potential implications for treatment strategies involving VCN-01 and durvalumab in HNSCC patients resistant to other therapies.
- : SEC 8-K (8.01): On June 5, 2026, Theriva Biologics, Inc. called its Special Meeting of Stockholders; however, there were not enough shares present to constitute a quorum, preventing the meeting from convening. This meeting aimed to seek stockholder approval for a warrant exercise proposal related to the issuance of up to 16,184,560 shares under a previously disclosed Inducement Agreement from October 16, 2025. The failure to convene the meeting necessitates that the Company call subsequent stockholder meetings every 60 days until approval is achieved or the warrants expire. The Company intends to provide further details regarding a new meeting date and related proxy materials to its stockholders. This situation could impact investor sentiment and the liquidity position of the Company due to the unfinalized approvals for warrant exercises.
- : SEC 8-K (8.01): On April 17, 2026, Theriva Biologics, Inc. announced an upcoming poster presentation at the AACR Annual Meeting regarding new data from the VIRAGE Phase 2b clinical trial of VCN-01 combined with gemcitabine/nab-paclitaxel in patients with metastatic pancreatic cancer. The presentation will feature findings on overall survival and response rates, highlighting significant benefits of the treatment combination. The poster, presented by Dr. Manuel Hidalgo, is scheduled for April 20, 2026, at the San Diego Convention Center, indicating ongoing advancements in cancer therapy. The press release serves to inform stakeholders about developments that may impact the company's positioning and investor interest in its clinical innovations.
- : SEC 8-K (8.01): On April 9, 2026, Theriva Biologics, Inc. convened a Special Meeting of Stockholders but could not establish a quorum, necessitating the rescheduling of the meeting. The meeting aimed to obtain Stockholder Approval for the exercise of up to 16,184,560 shares of common stock under a warrant inducement agreement dated October 16, 2025. The Company is required to continue calling stockholder meetings every 60 days until approval is obtained or the warrants are extinguished. This situation directly impacts investor relations and compliance with prior agreements.
- : SEC 8-K (8.01): On March 23, 2026, Theriva Biologics, Inc. announced the outcomes of a Type B End-of-Phase 2 meeting with the FDA regarding their Phase 3 clinical study for the drug VCN-01, targeting metastatic pancreatic ductal adenocarcinoma (PDAC). The FDA indicated general agreement with the proposed trial design, which incorporates repeat dosing and an adaptive design, building on the success of the earlier VIRAGE Phase 2 trial that improved overall survival and progression-free survival. A successful Phase 3 trial could support a biologics licensing application for VCN-01. Key aspects like primary and secondary endpoints, statistical expectations, and proposed dosing were also agreed upon by the FDA, indicating significant progress for the company in its clinical development plans.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Theriva Biologics funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2025 | Venture | $13.1M |
| Oct 2025 | Funding Round | $4.0M |
| Jul 2022 | Seed | $3.0M |
| Mar 2022 | Seed | $1.5M |
| Sep 2017 | Venture | $12.0M |
Leadership
- Steven Shallcross, Executive Officer, Director
- Jeffrey Kraws, Director
- John Monahan, Director
- Jeffrey Wolf, Director
- Scott Tarriff, Director
- Jeffrey Riley, Executive Officer, Director
- Ernest Milian, Vice President of Manufacturing
- Joseph Sliman, Executive Officer
Verified email and direct lines for Theriva Biologics’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
Theriva Biologics files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Companies similar to Theriva Biologics
- Camp4 Therapeutics Corp · Biopharma, Biotechnology, Health Care, Science And Engineering, Therapeutics
- AnHeart Therapeutics · Biopharma, Biotechnology, Health Care, Science And Engineering, Therapeutics
- Dimerix Limited · Biopharma, Biotechnology, Health Care, Therapeutics
- Cantargia AB · Biopharma, Biotechnology, Health Care, Therapeutics
- Newron Pharmaceuticals S.p.A. & EA Pharma Ltd · Biopharma, Biotechnology, Health Care, Therapeutics
About Theriva Biologics: questions and answers
What does Theriva Biologics do?
Theriva Biologics, Inc. was formerly known as Synthetic Biologics, Inc. Theriva™ is a clinical-stage immuno-oncology company developing oncolytic viruses intended to overcome the protective barrier surrounding solid tumors and selectively kill tumor cells. Our developmental therapies stem from the laboratory of Dr. Ramon Alemany, recognized world-wide as a key opinion leader in adenovirus technolo
Where is Theriva Biologics headquartered?
Theriva Biologics is headquartered in Rockville, Maryland, United States.
How many employees does Theriva Biologics have?
Theriva Biologics has about 22 employees.
Has Theriva Biologics raised funding?
Yes. Fundz has recorded 5 funding events for Theriva Biologics. The most recent, $13.1M, was in Oct 2025.
Who leads Theriva Biologics?
Ernest Milian is a Vice President of Manufacturing at Theriva Biologics.
What is the latest news on Theriva Biologics?
On Oct 14, 2025, SEC 8-K (1.01): On October 30, 2026, Theriva Biologics, Inc. entered into a Material Definitive Agreement with Biossil Labs Inc. for the sale of assets related to the oral β-lactamase product candidate SYN-004 and the carbapenemase product candidate SYN-006. The closing of the transaction was simult
Is Theriva Biologics a public company?
Yes. Theriva Biologics is publicly traded under the ticker TOVX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy